anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A tablet for the controlled release of an active pharmaceutical ingredient. The tablet comprises a core having a donut-like configuration with a cylindrical hole extending through the center of the core. The core of the body comprises at least one active pharmaceutical agent and at least one hydrophilic, water-soluble, polymeric carrier. The core is coated with a hydrophobic, water-insoluble material covering all of the core except that which is defined by the cylindrical hole. Also included is a method of preparing a tablet for the controlled release of an active ingredient. The method comprises the steps of blending an active pharmaceutical ingredient, a water-soluble hydrophilic, polymeric carrier, and optionally an excipient, to form a mix; compressing the mix; punching a tablet from the mix; coating the tablet in a water insoluble, hydrophobic coating, then drilling a hole through the coated tablet. A second embodiment of this method includes drilling a first hole through the tablet before coating the tablet, placing a rod through the first hole, dipping the tablet into the coating, and then removing the rod and drilling a second hole in the tablet which is larger than the first hole.
Prolonged use of high doses of orally active 17-alpha-alkyl androgens (e.g., methyltestosterone) has been associated with serious hepatic adverse effects (peliosis hepatis, hepatic neoplasms, cholestatic hepatitis, and jaundice). Peliosis hepatis can be a life-threatening or fatal complication. Long-term therapy with intramuscular testosterone enanthate has produced multiple hepatic adenomas. AZMIRO is not a 17 alpha-alkyl androgen and is not known to produce hepatic adverse effects associated with 17-alpha-alkyl androgens.   
Nonetheless, patients should be instructed to report any signs or symptoms of hepatic dysfunction (e.g., jaundice). If these occur, promptly discontinue AZMIRO while the cause is evaluated.
Participants randomized to this condition will complete six sessions during which they will write about their trauma for 20 minutes. The participant will receive instructions to write about the traumatic event that they feel affects them the most. For each session they will be instructed to write about the same event. For the first session, participants will complete psychoeducation and treatment rationale modules. The instructions for writing about the traumatic event will emphasize the importance of exploring their deepest emotions and thoughts at the time of the event, as well as providing detailed information about the event itself. For the remaining five writing sessions participants will be instructed to write about the same event and to focus on providing a detailed description of the part of the event that was most distressing to them, as well as how the event had affected their lives. A researcher will review the writing independently to ensure treatment compliance.
A medication dispensing device comprises a cartridge unit and a control unit. The cartridge unit comprises a cartridge housing defining a dispensing channel to allow passage of the dosage from the cartridge to the patient. A cartridge holds dosages, with a driven member engaging the cartridge. The driven member drives the cartridge to dispense a dosage. The control unit comprises a main housing for coupling to the cartridge housing. A driver member engages the driven member to actuate the driven member. A motor driven locking mechanism is moveable between locked and unlocked positions. When in the locked position the cartridge unit is secured to the control unit. When in the unlocked position the cartridge unit is separable from the control unit thereby providing access to the cartridge. A mobile computing device stores dosage availability and receives an authorized patient identification input before dispensing a dosage.
In a process wherein an aqueous alcoholic solution of a precipitate obtained by the acidification of an aqueous extract of liquorice root is contacted with a cation-exchange material, from which, after washing with an aqueous alcohol, substances having a cortisone-like activity are subsequently produced (see Group VI), the filtrate and washings from the cation exchanger are passed through an anion-exchanger, and the filtrate is evaporated at low pressure, dissolved in glacial acetic acid, and treated with potassium or ammonium acetate for the separation of potassium or ammonium glycyrrhizinate which is recrystallized.ALSO:Substances having a cortisone-like activity are obtained by a process comprising contacting a cation exchange material with an aqueous alcoholic solution of the precipitate obtained by acidification of an aqueous extract of liquorice root, washing the exchange material with an aqueous alcohol, and eluting the absorbed material with an aqueous alcoholic solution of an alkali, e.g. ammonia.  On evaporation, a brittle resin (fraction A) results.  (i) This is dissolved in water, a water-soluble alkaline earth salt, e.g. barium chloride, added, the inactive precipitate removed, and the supernatant liquid evaporated at low pressure to give an orange resin (fraction B).  (ii) Alternatively fraction A is dissolved in water and treated with lead acetate solution, when the greater part of the active factor is precipitated.  This is taken up by a dilute solution of ammonium sulphate to which a small amount of ammonia has been added, and the lead sulphate separated.  Operation (ii) may be applied to the liquid from the barium chloride treatment of (i) above.  (iii) In a third method, the eluate from the cation exchange column is concentrated, acidified to pH2, and the dark precipitate is removed.  The liquid is decolorized by charcoal, neutralized and evaporated at low pressure to a light yellow gum (fraction C).  An aqueous extract of this fraction may be extracted with butanol, whereby activity is concentrated in the butanol extracts.  The filtrate and washings from the cation exchanger may be passed through an anion-exchanger, and the filtrate evaporated at low pressure, dissolved in glacial acetic acid, and treated with potassium or ammonium acetate for the separation of potassium or ammonium glycyrrhizinate, which is recrystallized.
FIELD: therapy of respiratory diseases, mainly, asphyxia syndrome. SUBSTANCE: preparation represents suspension of physiologically acceptable surface-active substance containing, associated with it, calcium and/or magnesium ions dissolved in aqueous sodium chloride solution. Surface-active substances are selected from group consisting of phospholipides, neutral lipides and associated therewith proteins and/or synthetic lipides and recombinant proteins. They contain 25-70 mmole of calcium and/or magnesium ions per mole of organically extractable phospholipides. Concentration of these ions in aqueous medium is 1-3.5 mmole/l, that of sodium chloride is 33-150 mmole/l, and that of surface-active substance is 60-250 mg/ml. EFFECT: higher efficiency.
The invention relates to a content measuring method of a Chinese patent drug. The steps of the invention are that the chromatographic condition and the systematical employment and suitability test are the first step. The preparation of the solution for comparison is the second step of the invention. 3. After extracting by methyl alcohol, the extract solution of the preparation specimen is concentrated to the low alcoholic solution or the alcoholic-free solution. 4. After the purge process 3, the concentration solution of the extract solution is transferred to the macroreticular resin of a neutral alumina pole, wherein the lower portion is neutral alumina, and the upper portion is pre-treated macroreticular resin. The upper portion and the lower portion are washed by water and a grain alcohol solution of 10-25% sequentially, then the pole is eluted by the grain alcohol solution of 50-95%, and the eluent is collected and evaporated to dryness, further the residue is dissolved and has the constant volume and the filtration. The sequent filtration solution is achieved as the specimen solution. 5. According to the measuration, the solution for comparison of 10 mul and the specimen solution of 20 mul are precisely extracted separately, and the liquid chromatograph is injected, after measuring, the aim is achieved.
BACKGROUND: Hemodialysis (HD) and peritoneal dialysis (PD) are effective ways to treat end-stage renal disease (ERSD). This study aimed to investigate the differences in survival and the factors that influence it in patients with end-stage renal disease treated with HD or PD.
METHODS: We retrospectively analyzed factors related to all-cause death with renal replacement therapy and compared the long-term mortality between HD and PD strategies in patients with ESRD who started HD or PD treatment in our renal HD center between January 1, 2008, and December 1, 2021.
RESULTS: Overall, 1,319 patients were included, comprising 690 and 629 patients in the HD and PD groups, respectively, according to the inclusion criteria. After propensity matching, 922 patients remained, with 461 (50%) patients each in the two groups. There were no significant differences in the 1-, 2-, 3-, and 4-year mortality rates between the HD and PD groups (all p > .05). However, the 5- and 10-year mortality rates of the matched patients were 15.8%. 17.6% in the HD group and 21.0%. 27.3% in the PD group, respectively. The 5- and 10-year mortality rates were significantly lower in the HD group (all p < .05) as compared to the PD group. After matching, Kaplan-Meier curve analysis with log-rank test was performed, which showed a significant difference in the survival rates between the two groups (p = .001). Logistic multifactor regression analysis revealed that age, weight, hypertension, serum creatinine, and combined neoplasms influenced the survival rate of patients with ESRD (p < .05). In contrast, age, hypertension, parathyroid hormone (PTH), serum creatinine, and peripheral vascular diseases (PVD) influenced the survival rate of patients in the HD group (p < .05), and age and weight influenced the survival rate of patients in the PD group (p < .05).
CONCLUSIONS: This study found that long-term mortality rates were higher in the PD group than that in the HD group, indicating that HD may be superior to PD.
Sham Transcranial static magnetic field stimulation (tSMS) Sham tSMS will be delivered with non-magnetic metal cylinders, with the same size, weight and appearance of the magnets (MAG45s; Neurek SL, Toledo, Spain). Real and sham magnets will be held with an ergonomic helmet (MAGmv1.0; Neurek SL, Toledo, Spain).
Work package one involves the consolidation and further characterisation of a number of pre-existing UK-based clinical cohorts of patients with COPD. This involves collection of epidemiological and physiological data from patients and controls to enable a complete definition of disease phenotype. Work package two will examine microbiological and innate immune parameters in this cohort to define whether innate immune defects underpin the susceptibility to infectious exacerbation and progression of airways disease. It will perform microbiological characterisation of each group and will look at the behaviour of groups who have frequent infectious exacerbations of disease as compared to those that do not. Work package three will measure lung injury and work package four will define physiological characteristics including chest wall muscle function in the cohort.

Our work will sit within work package two. Researchers will collect data from patients within the cohort and in patients whom they may recruit locally and add to the cohort. Researchers will also share samples with other work packages (academic and industry based collaborators) as required to enable correlation of our findings with other investigators in our work package or other work packages. This project, which sits within work-package two will measure the capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
PURPOSE: The objective of this study is to investigate the associated risk factors of pulmonary infection in individuals diagnosed with chronic kidney disease (CKD). The primary goal is to develop a predictive model that can anticipate the likelihood of pulmonary infection during hospitalization among CKD patients.
METHODS: This retrospective cohort study was conducted at two prominent tertiary teaching hospitals. Three distinct models were formulated employing three different approaches: (1) the statistics-driven model, (2) the clinical knowledge-driven model, and (3) the decision tree model. The simplest and most efficient model was obtained by comparing their predictive power, stability, and practicability.
RESULTS: This study involved a total of 971 patients, with 388 individuals comprising the modeling group and 583 individuals comprising the validation group. Three different models, namely Models A, B, and C, were utilized, resulting in the identification of seven, four, and eleven predictors, respectively. Ultimately, a statistical knowledge-driven model was selected, which exhibited a C-statistic of 0.891 (0.855-0.927) and a Brier score of 0.012. Furthermore, the Hosmer-Lemeshow test indicated that the model demonstrated good calibration. Additionally, Model A displayed a satisfactory C-statistic of 0.883 (0.856-0.911) during external validation. The statistical-driven model, known as the A-C2GH2S risk score (which incorporates factors such as albumin, C2 [previous COPD history, blood calcium], random venous blood glucose, H2 [hemoglobin, high-density lipoprotein], and smoking), was utilized to determine the risk score for the incidence rate of lung infection in patients with CKD. The findings revealed a gradual increase in the occurrence of pulmonary infections, ranging from 1.84% for individuals with an A-C2GH2S Risk Score ≤ 6, to 93.96% for those with an A-C2GH2S Risk Score ≥ 18.5.
CONCLUSION: A predictive model comprising seven predictors was developed to forecast pulmonary infection in patients with CKD. This model is characterized by its simplicity, practicality, and it also has good specificity and sensitivity after verification.
Patients with stroke with uncontrolled glucose levels have higher mortality and poor post stroke outcomes. Controlling diabetes and other associated risk factors are effective ways to prevent initial strokes as well as stroke recurrence. Diabetes increases ischemic stroke incidence in all age groups, individuals with diabetes are more likely to suffer from hypertension, myocardial infarction and high cholesterol than individuals without diabetes have been linked to a greater risk of stroke. Smoking is a major cause of cardiovascular disease and causes one of every four deaths from cardiovascular disease. Smoking can raise triglycerides (a type of fat in your blood), Lower "good" cholesterol (high-density lipoprotein), Make blood sticky and more likely to clot, which can block blood flow to the heart and brain, Damage cells that line the blood vessels, Increase the buildup of plaque (fat, cholesterol, calcium, and other substances) in blood vessels and cause thickening and narrowing of blood vessels.The idea of lifestyle includes a broad variety of subjects, containing substantial life, spiritual life and other issues. Physical activity, smoking, alcohol consumption, nutrition and other aspects to measure lifestyle used by Chinese scientists. Health promoting lifestyle (HPL) is defined as "a multi-dimensional pattern of self-initiated actions and perceptions that serve to maintain or enhance the level of wellness, self-actualization, and fulfillment of the individual". It assesses a personal well-being activity that involves physical activity, dieting, spiritual growth, interpersonal relationships, health responsibility, and stress management, and would lead to enhaning wellbeing condition
PURPOSE:The titled composition useful as a water repellent, etc., having improved stability, obtained by emulsifying or solubilizing a silicone oil in the presence of protein, protein decomposition product, surface active agent, etc. in a polyhydroxy compound or its aqueous solution. CONSTITUTION:<=90wt%, preferably 30-70wt% based on total emulsion or solution of silicone oil (e.g., straight-chain methylsilicone oil, etc.) is emulsified or solubilized with stirring in the presence of >=0.05, especially <=5wt% based on total amount with solution of protein (e.g., sodium caseinate, etc.), protein decomposition product (decomposition product by protease, etc.) and/or a surface active agent in >=30wt% based on total amount with protein, etc. of a polyhydroxy compound (e.g., propylene glycol, etc.) or its aqueous solution. The silicone oil is preferably blended with a solution of the polyhydroy compound kept at temperature to make it liquid. The composition is easily emulsified or dispersed into water only by adding it to water with stirring.
<P>PROBLEM TO BE SOLVED: To provide a system and the like for providing medical information concerning with traveling abroad before travel for allowing a traveler to go abroad without concern.  <P>SOLUTION: A storage device of a server 1 stores travel information associated with a destination of travel and medical information concerning with the destination. The server 1 receives a travel destination from a PC 2, retrieves travel information based on the travel destination, and transmits the corresponding medical information to the PC 2. The storage device of the server 1 stores medical certificate information written in English for the traveler, and when transmission of the medical certificate is required from a doctor overseas in emergency, the server 1 transmits the medical certificate written in English about the traveler if the doctor is registered. The server 1 transmits a message stating transmission of the medical certificate to the traveler and his/her family and the like.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Induction-3 wks (cyclophosphamide day 0\&1, doxorubicin hydrochloride \& vincristine sulfate day 0-2 \& filgrastim(G-CSF) day 3 crs 1,2,4 \& 6.) Crs 3 \& 5 (etoposide day 0-2, cisplatin day 0-3, G-CSF day 4). Pts undergo unpurged PBSC collection until the target cell count is reached. Surgical resection of the tumor after crs 5 of induct. CR, VGPR, PR after induct receive consolidation (melphalan day -7 to -5, carboplatin \& etoposide day -7 to -4. purged peripheral blood stem cell transplantation infusion day 0, G-CSF 4 hrs post transplant. Day 66, isotretinoin 2x day/14 days. Isotretinoin every 4 wks 6 crs. After consol (28 days from stem cell infusion), radiation therapy 1x day/7 days. Not undergoing autologous bone marrow transplantation receive maintenance(cyclophosphamide 30 mins, topotecan hydrochloride days 0-4, G-CSF day 5). Maint every 3 wks/3 crs. Radiation therapy and Isotretinoin 2x day/14 days then every 4 wks for 6 crs.
In this arm, participants will wear their clinically prescribed laminated socket. This period is approximately 2 weeks.
Connect.Parkinson is a national study examining the feasibility and effectiveness of using video calls to bring expert Parkinson disease care directly into patients' homes. Currently, access to care for Parkinson disease is limited by distance, disability, and the distribution of doctors. Approximately 200 individuals with Parkinson disease (who due to distance, disability, disparity, or doctor distribution have limited access to care) will be randomized to one of two arms in this comparative effectiveness study. The first (control) arm will be the individual's "usual care" supplemented by educational materials on their condition. This usual care may include care from a generalist, care from a neurologist, or in-person care from a Parkinson specialist. The care received by the control group will vary but will be an accurate reflection of usual care in this country. The second (intervention) arm will be usual care supplemented by educational materials and care from a Parkinson disease specialist delivered via web-based video conferencing into the patient's home. The participants will also be asked with they have a primary care partner, and care partners will be invited to enroll, for a total of approximately 400 participants.
The invention discloses a traditional Chinese medicine for treating melanosis coli. The traditional Chinese medicine is prepared from the following traditional Chinese medicinal materials: Clinopodium chinense (Benth.) O. Kuntze[Calamintha Chinensis Benth.], herb of wingystem veronicatrum, leaf bud of Thatch screwpine, flowers of Chinese small iris, Deutzia ningpoensis Rehd., Camellia sinensis (L.)O.kuntze.f.macrophyll (Sieb.)Kitamura, cowrie shell, caesalpinia bonduc, delavay dobinea root, licorice sections, crab fossil, hungaian morning glory root, Veronica ciliata Fisch., rhizome of Chinese twinleaf, elephant gallbladder, herb of big striga, erigeron annuus, cinchona bark, Indian stringbush root and ceylon helminthostachys rhizome. The traditional Chinese medicine is prepared by taking the pure natural traditional Chinese medicinal materials as raw materials, treats both symptoms and root causes, is definite in curative effects, and is free of toxic and side effects, and relapse of melanosis coli seldom occurs.
Ankylosing spondylitis is a chronic, inflammatory disease that affects the axial spine, causing progressive limitation on the spine and leading to a decrease in quality of life. Anti TNF drugs are frequently used in the treatment of ankylosing spondylitis and teaching activities in improving patient compliance and patient compliance are very important in the success of this treatment. This study was carried out to develop an android mobile application for the subcutaneous (SC) anti-TNF drug administration of ankylosing spondylitis patients and to evaluate its effect on drug administration.

The universe of this experimental designed posttest control group research is consisted of patients prescribed subcutaneous anti-TNF drug due to ankylosing spondylitis in Eskişehir Osmangazi University Health, Application and Research Hospital Rheumatology Polyclinic between 15 December 2017 - 30 December 2019. The patients who constituted the sample of the study were assigned by lot to mobile application and the education booklet groups. The mobile application that includes follow-up and information related to disease information, anti-TNF drug application and management was transferred to mobile phones of patients in mobile application group via bluetooth technology and installed. The patients in the education booklet group were given an education booklet on disease information, antiTNF drug administration and management. In the study, patients were evaluated once before anti-TNF drug treatment and every 6 weeks during 6 months (4 times) after treatment. The data of the study were collected by means of an individual identification form, BASDAI, BASFI, ASQoL and Subcutaneous Anti-TNF Treatment Questionnaire.